Home » Topics » BioWorld Science, Endocrine/metabolic

BioWorld Science, Endocrine/metabolic
RSS

Biophytis Institut and Universite Pierre et Marie Curie patent GDF-8 inhibitors

Dec. 4, 2015

Novo Nordisk starts phase I trial comparing NNC-0143-0406 and insulin aspart

Dec. 4, 2015

FDA places Zafgen's phase III trial of beloranib in Prader-Willi syndrome on full clinical hold

Dec. 3, 2015

Apricus confirms strategy for fispemifene, following FDA guidance on enclomiphene

Dec. 3, 2015

Phase I trial results of T1D immunotherapy with autologous polyclonal Tregs

Dec. 3, 2015

Kamada provides update on alpha1-antitrypsin development in type 1 diabetes

Dec. 3, 2015

Novo Nordisk licenses antibodies targeting insulin receptor from XOMA

Dec. 2, 2015

Repros Therapeutics receives FDA complete response letter for enclomiphene

Dec. 2, 2015

HTIT licenses marketing rights to Oramed's oral insulin in China

Dec. 2, 2015

European Comission approves Horizon's Ravicti

Dec. 1, 2015

Popular Stories

Today's news in brief
BioWorld
BioWorld briefs for April 6, 2026.
Hengrui discovers new Nav1.8 blockers
BioWorld Science
Researchers from Jiangsu Hengrui Pharmaceuticals Co. Ltd. and Shanghai Hengrui Pharmaceutical Co. Ltd. have patented new sodium channel protein type 10 subunit α...
News in brief
BioWorld Asia
BioWorld Asia briefs for March 31, 2026
Hematopoietic stem cell research points to leukemia’s early roots
BioWorld Science
Hematopoietic stem cell (HSC) research over the past century has shown that leukemia may be driven by an invisible hand of inflammation. The bone marrow and...
Infinimmune presents preclinical data on anti-IL-22 antibody for atopic dermatitis
BioWorld Science
Infinimmune Inc. has recently presented results at the annual American Academy of Dermatology conference regarding their anti-IL-22 antibody IFX-101 for the...